Cord Blood Banking Leader Cryo-Cell Declares Initiation of Regular Quarterly Cash Dividend
Dividend Announcement: Cryo-Cell International, Inc. has approved a quarterly cash dividend of $0.25 per share for shareholders as of November 15, 2024, with payment expected on November 29, 2024. The Board will regularly review the dividend policy based on the company's financial performance and capital needs.
Company Overview: Founded in 1989, Cryo-Cell is the first private cord blood bank, serving over 500,000 parents globally. It operates both private and public banking programs, has received multiple accreditations, and aims to provide high-quality cryopreservation services and develop cellular therapies.
Trade with 70% Backtested Accuracy
Analyst Views on CCEL
About CCEL
About the author
Cryo-Cell International Inc Reports Decrease in Q3 Profit
Earnings Decline: Cryo-Cell International Inc reported a decrease in earnings for the third quarter, with profits falling to $0.75 million ($0.09 per share) from $1.05 million ($0.13 per share) in the same period last year.
Revenue Drop: The company's revenue also declined by 3.0%, totaling $7.83 million compared to $8.07 million in the previous year.
Insider Buying Update for Friday, September 12: CCEL, AROW
Cryo-Cell International Insider Activity: Chairman and Co-CEO David Portnoy purchased 42,900 shares of CCEL at $4.43 each, totaling $189,986, and is currently up 6.1% based on recent trading highs.
Arrow Financial Insider Activity: CFO Penko Krassimir Ivanov bought 5,000 shares of AROW at $29.10 each for a total of $145,499, with previous investments totaling $391,248 at an average of $29.14 per share.
